Clinical research
Clinical-stage biotech company Celcuity announced Thursday that it had entered into a global licensing agreement with Pfizer to develop and commercialize gedatolisib, the latter company’s first-in-class PI3K/mTOR inhibitor for the treatment of breast cancer.
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.
Bristol Myers Squibb announced topline data from the Phase III CheckMate -648 trial on Thursday, with positive results in esophageal cancer.
Eli Lilly and Company and Incyte announced today that their Phase III COV-BARRIER study of Olumiant (baricitinib) plus standard of care (SoC) compared to placebo plus SoC failed to hit statistical significance against COVID-19 for its primary endpoint.
The $3.1 million NCATS grant will help the company test SPI-1005 in two trials, both OK’d by the U.S. Food and Drug Administration (FDA) last August.
Shares of FibroGen were crashing this morning after the company unsuccessfully attempted to express confidence in the benefit/risk profile of its anemia drug, Roxadustat.
Ionis Pharmaceuticals unleashed a string of news releases about activities at the company, including a partnership with Progenity and the launch of a Phase III trial for amyotrophic lateral sclerosis.
The U.S. FDA issued a Complete Response Letter (CRL) over Acadia Pharmaceuticals’ supplemental New Drug Application (sNDA) for Nuplazid for hallucinations and delusions associated with dementia-related psychosis.
It was a busy week for clinical trial news. Here’s a look.
Days after announcing the U.S. Food and Drug Administration (FDA) has cleared the next clinical trials to launch for its lead natural killer (NK) cell therapies, NKMax America announced it has renamed itself NKGen Biotech.
PRESS RELEASES